MedTrace Logo

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-08-03

No results posted yet for this study

Summary

Given its anti-viral, anti-oxidative, immune-enhancing, cytokine-modulating, and anticoagulant properties, the investigators hypothesize that Selenium infusion at supranutritional doses for moderately-ill, severely-ill, and critically-ill COVID-19 patients will prevent further clinical deterioration thus decreasing overall mortality and improving survival. To test this hypothesis, a prospective, single-center, phase II trial is proposed to assess the efficacy of Selenium in hospitalized adult patients with moderate, severe, and critical COVID-19 infections.

Conditions

  • Covid19

Interventions

DRUG

Selenium (as Selenious Acid)

Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.

OTHER

Placebo

Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.

Sponsors & Collaborators

  • Pharco Pharmaceuticals

    collaborator INDUSTRY

  • CHRISTUS Health

    lead OTHER

Principal Investigators

  • Mohamed S Ghoweba, MD · CHRISTUS Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-15
Primary Completion
2021-11-15
Completion
2021-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04869579 on ClinicalTrials.gov